Rubedo Life Sciences Expands to Europe Before First Clinical Trial

Rubedo Life Sciences, a biopharmaceutical company dedicated to creating innovative therapies for age-related diseases, announced the establishment of its European headquarters and clinical operations in Milan, Italy. This strategic move precedes their first-in-human, Phase 1 clinical trial for their lead candidate, RLS-1496, scheduled to begin early next year in Europe. RLS-1496 is a pioneering treatment targeting inflammatory skin conditions. This trial marks Rubedo's first clinical venture outside their California headquarters, highlighting the global significance of age-related diseases.

CEO and Co-Founder of Rubedo Life Sciences, Marco Quarta, expressed enthusiasm about transitioning to a clinical stage company. He emphasized the opportunity to harness top-tier talent and resources in Europe to convert their groundbreaking research into leading therapies for skin conditions influenced by senescent cells and aging. Quarta also acknowledged the support of prominent European investors such as CDP Venture Capital, underscoring the company's expansion into Europe and its development into a global entity.

Agostino Scornajenchi, CEO and General Manager of CDP Venture Capital, echoed this sentiment, highlighting the investment as a testament to Italy's strategic focus on AI and biotech sectors. He affirmed their commitment to fostering innovation and reinforcing Italy's status as a hub for high-impact industries by supporting Rubedo Life Sciences' growth.

The Phase 1 clinical trial of RLS-1496 will involve patients with specific skin conditions, primarily aiming to assess safety. Secondary goals will include evaluating cellular senescence and disease-related biomarkers. RLS-1496, administered topically, aims to provide a more efficient proof of concept compared to systemic therapies.

Rubedo Life Sciences is recognized for developing a broad range of pioneering therapies targeting cells responsible for chronic age-related illnesses. Their proprietary ALEMBIC™ drug discovery platform has created novel small molecules designed to selectively target various senescent cells, which contribute to the progression of numerous chronic diseases, including those affecting the lungs, skin, and neurological systems, as well as cancer and fibrosis. The company's leadership comprises experts and pioneers in chemistry, technology, and life sciences, with extensive experience in drug development and commercialization from both large pharmaceutical and leading biotech companies. Rubedo Life Sciences is headquartered in Sunnyvale, California.